TuHURA Biosciences, Inc. (HURA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.14+1.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HURA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
HURA — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-09-04
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. On September 2, 2026, the Company received and bor…
Why it matters: The credit facility is key for funding operations. Updates on its use will show financial health.
Supportive ifTuHURA says it used the credit line to fund its operations.
Worry ifTuHURA has trouble accessing or using the credit line.
Why it matters: Compliance with Nasdaq is crucial for TuHURA to maintain its listing. Any updates will impact investor confidence.
Worry ifManagement has a plan to meet Nasdaq rules in the next quarter.
Less concerning ifManagement fails to provide a clear plan or timeline for compliance.
Why it matters: The earnings report will show if the company continues to miss expectations. This is crucial for investor confidence.
Worry ifQ2 earnings report shows a loss greater than the previous quarter's loss of $X million.
Less concerning ifQ2 earnings report shows a profit or a smaller loss than the previous quarter.
Why it matters: This designation would help the drug develop and succeed in the market.
Supportive ifThere is an official announcement of orphan drug designation for TBS-2025 in AML.
Worry ifFailure to receive orphan drug designation for TBS-2025 in AML.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$289 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $1,004 loss on $10,000 · 10.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,314 loss on $10,000 · 83.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Funding updates can change how stable operations are. They also affect investor trust in growth.
Watch forThere is news about a successful drawdown from the $50 million credit line for operations.
Also watch forThere is news about issues accessing the credit line or problems with funding.
Why it matters: Starting this trial is a key step in TuHURA's pipeline and signals progress.
Supportive ifAnnouncement of the initiation of the Phase 1b/2 trial for TBS-2025 in mut NPM1 r/r AML.
Worry ifDelay or cancellation of the Phase 1b/2 trial initiation for TBS-2025.
Why it matters: Updates on cash runway show if TuHURA can fund operations and trials.
Watch forNews of new funding sources or successful use of the credit facility.
Also watch forCash runway is shorter than expected or funding problems occur.
Why it matters: Good feedback would show that TBS-2025 is on the right track. This would help investors feel more confident.
Supportive ifThe FDA gave safe-to-proceed feedback on the TBS-2025 IND application.
Worry ifNegative feedback from the FDA on the TBS-2025 IND application.
Why it matters: The health care sector is slowing. If growth re-accelerates, it may help TuHURA's outlook.
Supportive ifHealth care sector revenue growth re-accelerates back toward its highs.
Worry ifHealth care sector revenue growth continues to decelerate.
Why it matters: This meeting is crucial for the development of TBS-2025. It could impact the timeline for trials.
Supportive ifConfirmation of the FDA meeting date for TBS-2025's IND application.
Worry ifNo meeting scheduled or significant delays in the FDA process.
Why it matters: Addressing compliance is crucial for TuHURA's stock stability. Failure to comply could lead to delisting.
Worry ifTuHURA has a clear plan. They have a timeline to meet Nasdaq rules.
Less concerning ifNo progress reported on compliance efforts by the next earnings date.
Why it matters: Getting this designation can boost the drug's market potential. It can also attract more investors.
Supportive ifAn announcement says IFx-2.0 got Orphan Drug Designation for MCC.
Worry ifThe FDA denies the Orphan Drug Designation for IFx-2.0 in MCC.
Why it matters: Finishing enrollment is key for moving the trial forward. It could lead to important data.
Supportive ifAnnouncement that enrollment in the Phase 3 study of IFx-2.0 is completed.
Worry ifEnrollment is delayed or falls short of expectations.
Why it matters: High cash burn may show financial issues for TuHURA's operations.
Worry ifIn Q3, cash burn is over $5 million. This shows spending is too high.
Less concerning ifCash burn is under $5 million. This shows better money management.